Consistently, WGS analysis in 1,309 T-ALL samples from Children’s Oncology Group clinical trial AALL0434 (40) showed that 8.8% of patients had MYB amplifications, of which 97% involved the H-Me (Figure 6A). Here, MYB is linked to acute lymphoblastic leukemia.